Additional File 2. Top three areas of impact of COVID-19 on rare disease patients from each jurisdiction group

	Most frequently identified	2 nd most frequently identified		3 rd most frequently identified		Least frequently identified
Overall (n=189)*	Reduced access to healthcare (n=81; 43%)	Patient's daily living and social life (n=49; 26%)		Patient's physical health (n=27; 14%)		Financial impact (n=12; 6%)
HKSAR, China (n=42)*	Reduced access to healthcare (n=19; 45%)	Patient's daily living and social life (n=13; 31%)		Patient's physical health (n=6; 14%)		Financial impact (n=0; 0%)
Mainland China (n=65)*	Reduced access to healthcare (n=32; 49%)	Patient's daily living and social life (n=14; 22%)		Patient's physical health (n=10; 15%)		Patient's psychological health (n=3; 5%)
Australia, New Zealand (n=49)*	Reduced access to healthcare (n=17; 49%)	Patient's psychological health (n=12; 24%)		Patient's daily living and social life (n=9; 18%)		Financial impact (n=4; 8%)
Japan, Singapore, Taiwan (n=14)*	Patient's daily living and social life (n=6; 43%)	Reduced access to healthcare (n=4; 29%)		Financial impact (n=2; 14%)		Patient's psychological health (n=0; 0%)
				Patient's physical health (n=2; 14%)		
India, Malaysia, Philippines (n=16)*	Reduced access to healthcare (n=5; 31%)	Patient's psychological health (n=4; 25%)		Patient's physical health (n=2; 13%)		Financial impact (n=0; 0%)
	Patient's daily living and social life (n=5; 31%)					
Reduced healtho access	care Physical health impact	Social impact	Psycholog	ical impact	Financial impact]

 * Participants could list up to 3 areas of patient impact

COVID-19 coronavirus disease of 2019; HKSAR Hong Kong Special Administrative

Region